It was reported, that K-RAS mut NSCLC patients showed a prolonged overall survival after a Nivolumab treatment compared to K-RAS wt patients, who did not benefit from a PD-1 blockade[76]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.